Demand for Plasma Fractionation Market to Expand 1.5x Through 2026

Fact.MR forecasts bullish prospects for the plasma fractionation market. The utilization of immunoglobulins has augmented in the last few years. Plasma-derived immunoglobulins are giving a new narrative to healthcare across a wide range of autoimmune and inflammatory diseases.

For detailed insights on enhancing your product footprint, request for a sample here - https://www.factmr.com/connectus/sample?flag=S&rep_id=4806
 
This widespread applicability is anticipated to leverage market prospects for plasma fractionation, pegged to witness a noteworthy 7% CAGR

In addition, consistent technological innovations for developing efficient and cost-effective procedures for fractioning proteins shall also augment the plasma fractionation market. Therapies such as Ceruloplasmin and IgA are some examples of such innovations. Based on these trends, the plasma fractionation market is anticipated to scale up in the future, expanding 1.5x in the forecast period. (2020-2026)

Key Takeaways from the Plasma Fractionation Market Study:

• By product, intravenous immunoglobulins are poised to maintain their hegemony in the plasma fractionation market. The segment is poised to capture more than 2/5th of the overall market. High incidence of autoimmune diseases shall drive growth within this segment.

For critical insights on this market, request for methodology here - https://www.factmr.com/connectus/sample?flag=RM&rep_id=4806

• By application, the neurology segment shall leverage almost 2.0x, capturing more than 2/5th of the plasma fractionation market. Rising prevalence of neurological disorders is attributed as an important growth driver for this segment. More than 450 million people worldwide are affected by neurological disorders.
• By end-user, hospitals and clinics shall account for a significant chunk of revenue, capturing nearly 70% of the plasma fractionation market. Robust expansion of hospitals as a result of significant investments is set to augment the share of this segment.

Plasma Fractionation Market Segmentation

Fact.MR has studied the plasma fractionation market with detailed segmentation on the basis of product, application, end-user and region.

For in-depth competitive analysis, buy now – https://www.factmr.com/checkout/4806

Product
• Immunoglobulins:
o Intravenous Immunoglobulins
o Subcutaneous Immunoglobulins
• Coagulation Factor Concentrates:
o Factor VIII
o Factor IXF
o actor XIII
o Prothrombin Complex Concentrate
o Von Willebrand Factor (VWF)
o Fibrinogen Concentrates
• Albumin
• Protease Inhibitors
• Other Plasma Products

Application
• Neurology
• Immunology
• Hematology
• Critical Care
• Pulmonary
• Other Applications

Read More Trending and Similar Reports from Fact.MR – https://www.globenewswire.com/en/news-release/2019/05/10/1821826/0/en/Dental-Anesthetics-Sales-Surge-in-Line-with-Growing-Need-for-Painless-Value-Based-Oral-Care-Procedures-Fact-MR.html

Stakeholders’ Consensus on Novel Offerings to Herald an Era of Profitability

The plasma fractionation market consists of a host of market players. These include: CSL Behring, Shire plc, Sanquin, Biotest AG, GRIFOLS, Baxter International Inc., Kedrion, Octapharma USA Inc. to name a few. Innovative offerings are key growth strategies adopted by market players.

CSL Behring, for instance, markets the Privigen, Carimune, Snadoglobulin and Hizentra solutions. Sanquin produces four types of plasma products using various isolation techniques: coagulation factors, protease inhibitors, immunoglobulins and albumin. The company also offers contract fractionation services.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
E: sales@factmr.com
Website: https://www.factmr.com
Content Source: https://www.factmr.com/media-release/1576/global-plasma-fractionation-market

About Us:
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

This release was published on openPR.